Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with ...

What you need to know The prevalence of heart failure across Europe is estimated to be 1-2% of adults.1 In the UK, this places a substantial burden on patients and healthcare resources, including ...

—These study results support the use of a remote, algorithm-based, navigator-led titration strategy to optimize the management of patients with heart failure with reduced ejection fraction (HFrEF).

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...

Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.

A medication that is currently used for chronic kidney disease in patients with type 2 diabetes has been found to reduce the risk of worsening heart failure and cardiovascular death in certain people ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...